Merck, MTOX1006-1VL, BCRP/MRP2 Double Knockout Caco-2 Cells

General description
The C2BBe1 cells, a subclone of Caco-2 cells, correspond to ATCC CRL-2102. The BCRP and MRP2 knockout C2BBe1 cells are adenocarcinoma, epithelial cells from a human caucasian male (aged 72 years) with functional double knockout of the ABCG2 and ABCC2 (BCRP/MRP2) efflux transporters.
Application
The following posters and articles demonstrate how Caco-2 cells can be used for cell based assays:

Transporter Function in Caco-2 Cells with Targeted P-Glycoprotein, MRP2 and BCRP Gene Knockout Using Zinc Finger Nucleases

Comparison of Function and Relative Transporter Protein Concentrations in Caco-2 Cells with Single and Double Knockouts of the ABCB1, ABCG2, and ABCC2 Genes

Caco-2 Transporter Knockout Cell Based Assays
Features and Benefits
The Caco-2 subclone C2BBe1 cells are ideal for transporter analysis as they express multiple transporters, are human derived, and grow in a homogenous monolayer that forms tight juntions which is necessary for efflux ratio analysis. Other benefits include:

• A functional double knockout of the BCRP gene and MRP2 gene eliminates the reliance on chemical inhibitors to determine if a compound is an MDR1 substrate
• The vial format enables the BCRP and MRP2 knockout cells to be included in standard drug transporter protocols
• Human assay with no interference from animal inhibitors
• Overcome the limitations of RNAi and knockdown cell lines that arise from remaining transporter functionality

Legal Information
ADME/Tox Cell Lines License
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.